Pharmaceutical Exporter from India to Türkiye.
Türkiye is a top-twenty world pharmaceutical market, roughly USD 6 billion and the nineteenth largest globally, but it is not an open finished-generics import market. Around ninety percent of units are produced domestically, a localisation mandate ties reimbursement to local production, and imports concentrate in high-value biologics, specialty products, and active ingredients. M Care Exports supplies into that reality honestly: WHO-GMP active pharmaceutical ingredients and intermediates to Turkish manufacturers, specialty and oncology finished products where local production is not feasible, and local-partner fill-finish support, with TİTCK CTD dossiers and freight through Istanbul and Mersin. We tell you which lane your molecule fits before you commit.
TİTCK, a local MA holder, and an own-inspection GMP regime
Türkiye's medicines regulator is TİTCK, the Türkiye İlaç ve Tıbbi Cihaz Kurumu, under the Ministry of Health. Marketing authorisation runs on a full ICH CTD or eCTD dossier, and a Türkiye-based marketing-authorisation holder or local representative is mandatory; a foreign manufacturer cannot hold the registration directly. The dossier review is a 210-day statutory clock, 180 days for priority products, and closes in roughly eight to twelve months on a clean file.
The step most Indian exporters underestimate is GMP. TİTCK generally does not accept an EU GMP certificate alone. It conducts its own on-site inspection of the foreign manufacturing site as a prerequisite to authorisation, and the inspection queue can add twelve to eighteen months of lead time before the review even begins. M Care plans Türkiye programmes against that inspection lead time first, then the dossier clock, because sequencing them wrongly is what makes Türkiye entry feel slow.
The defining commercial feature is the localisation policy. Since 2016 Türkiye has linked SGK reimbursement to a commitment to local production for molecules that can feasibly be manufactured domestically. The policy was material enough to draw a WTO dispute, DS583, from the European Union. For an Indian supplier this means pure imported finished generics for common molecules face a reimbursement and pricing wall, so the workable routes are active-ingredient supply, specialty products with no local equivalent, and local-partner fill-finish.
On compliance, M Care holds WHO-GMP and works with Indian partners that include EU-GMP-inspected sites; we are not US-FDA registered. For a Turkish manufacturer sourcing API under a CEP or DMF, or a local MA holder bringing in a specialty finished product, our WHO-GMP and EU-GMP credentials and CTD-ready documentation map onto what TİTCK and Turkish partners expect.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · [email protected] · Mon–Sat 09:30–18:30 IST
How we serve manufacturers, MA holders, and specialty buyers in Türkiye
API and intermediate supply
WHO-GMP active pharmaceutical ingredients and intermediates to Turkish manufacturers for local fill-finish and formulation, with CEP or DMF support, the lane that works cleanly under the localisation regime.
Specialty and niche finished products
Oncology, specialist injectables, and low-volume molecules with no feasible local production, where finished import is still commercially and regulatorily viable.
Local-partner fill-finish support
Bulk and semi-finished supply structured for a Turkish licensed-manufacture or fill-finish partnership, so the finished product qualifies as locally produced for SGK purposes.
TİTCK CTD dossiers
Full ICH CTD or eCTD assembly to TİTCK expectations, with the manufacturer-side GMP-inspection logistics coordinated with the local MA holder against the inspection queue.
Turkish labelling readiness
Primary product with English master-carton labelling plus the SmPC, stability, and documentation the local partner needs to complete Turkish-language packaging and the 2026-2027 e-leaflet and 2D-barcode requirements at a TİTCK-authorised facility.
Honest lane selection
We tell you up front whether your molecule fits API supply, specialty finished import, or local-partner fill-finish, rather than promising open finished-generic access that the localisation mandate will not honour.
Routing pharmaceuticals and APIs through IST and the Port of Mersin
Air freight runs Mumbai to Istanbul Airport (IST), the Turkish Cargo hub, at roughly six hours forty-five minutes wheels-up with departures every one to two days. Turkish Cargo holds IATA CEIV Pharma certification at Istanbul, which is the credential that matters for temperature-controlled biologicals and sensitive active ingredients. For cold-chain product we move air via IST with active or passive shippers chosen against forecasted apron dwell.
Sea freight routes to the Port of Mersin, Türkiye's principal pharmaceutical seaport on the Mediterranean coast, at roughly fourteen to fifteen days from Nhava Sheva or Mundra. Ambient-stable APIs, intermediates, and finished product in bulk move by sea; we plan ETAs against realistic schedules rather than optimistic booking confirmations and coordinate with the Turkish consignee's customs broker.
Turkish customs clearance requires the local marketing-authorisation holder or licensed importer of record, the TİTCK marketing-authorisation reference per registered SKU, commercial documentation, and, for finished product, Turkish-language packaging completed at a TİTCK-authorised secondary-packaging facility inside Türkiye. For API supply into a Turkish manufacturer, the documentation set is the manufacturer's import licence, the CEP or DMF reference, and the certificate of analysis per batch. We pre-stage the documentation in the format the Turkish partner's broker uses.
What Türkiye actually sources from India
Active pharmaceutical ingredients and intermediates are the largest and cleanest Indian-supply category into Türkiye. Turkish manufacturers, with their strong domestic fill-finish base, source APIs for antibiotics, cardiovascular molecules, antidiabetics, and a wide generic range from Indian and Chinese producers. This is the lane the localisation policy actively encourages, because the finished product is then made in Türkiye.
Specialty and high-value finished products are the second category. Oncology cytotoxics, specialist injectables, and niche molecules where no Turkish producer makes the line can still enter as finished imports through a local MA holder, since the localisation test only bites where local production is feasible. These are lower-volume, higher-value lines that suit a focused Indian specialty supplier.
Finished generics through local partnership are the third route. Where a molecule is high-volume and reimbursement-dependent, the commercially sound path is to supply bulk or semi-finished product into a Turkish fill-finish partner so the output qualifies as locally produced. M Care structures supply around whichever of these three the molecule and the buyer's licence support.
A Turkish generic manufacturer with its own TİTCK-licensed fill-finish lines approached us to secure a steady API supply for two cardiovascular molecules and one oral antidiabetic, after currency swings had made their previous single-source arrangement unreliable on both price and lead time. The brief was not finished product, it was consistent WHO-GMP active ingredient with the documentation their own dossiers and TİTCK inspections would stand behind. We evidenced WHO-GMP for each API source, provided the DMF references and full certificate-of-analysis history, and structured shipments air via Istanbul for the higher-value cardiovascular API and sea via Mersin for the ambient antidiabetic. Because the finished product is manufactured in Türkiye, the arrangement sits cleanly inside the localisation regime and the reimbursement question never arises against us. The manufacturer has since asked us to scope a third molecule and to hold safety stock at a bonded position to absorb lira-driven ordering swings.
A market that rewards honesty about localisation, not blanket import promises
Türkiye is the market where an unrealistic pitch is exposed fastest. Anyone promising open finished-generic access at volume is either ignoring the localisation mandate or the SGK reference-pricing squeeze, and a serious Turkish manufacturer or MA holder knows it. M Care's value is the opposite: we map your molecule to the lane that actually clears, API and intermediate supply into local production, specialty finished imports with no feasible local equivalent, or a local fill-finish partnership, and we say so before you spend on a dossier or a GMP inspection.
We are honest about the friction. The TİTCK own-inspection GMP requirement adds real lead time that has to be sequenced first. Lira volatility and the EUR-referenced pricing coefficient compress finished-product margins, which is exactly why the API and specialty lanes are the durable ones. And Turkish-language packaging plus the 2026-2027 e-leaflet and 2D-barcode rules mean finished product is completed locally, not shipped retail-ready from Mumbai. Within those realities, the India-to-Türkiye lane is a strong one, for manufacturers sourcing active ingredients, for MA holders bringing in specialty lines, and for partners building local fill-finish on Indian bulk supply.
Sourcing, regulatory, and localisation questions Turkish buyers ask
Who regulates pharmaceutical imports into Türkiye?
TİTCK, the Turkish Medicines and Medical Devices Agency (Türkiye İlaç ve Tıbbi Cihaz Kurumu) under the Ministry of Health, is the regulator. Marketing authorisation runs on a full ICH CTD or eCTD dossier and a Türkiye-based marketing-authorisation holder or local representative is mandatory. Unlike many markets, TİTCK generally does not accept an EU GMP certificate alone: it conducts its own on-site GMP inspection of the foreign manufacturing site as a prerequisite, which can add twelve to eighteen months of lead time before the review clock starts. M Care prepares the CTD pack to TİTCK expectations and coordinates the manufacturer-side GMP inspection logistics with the local MA holder.
Can I simply import finished Indian generics into Türkiye?
Often not as a blanket strategy, and we are honest about that. Türkiye runs a localisation policy: roughly ninety percent of medicine units are produced domestically, and a drug that can feasibly be manufactured in Türkiye is expected to be, or it risks exclusion from SGK reimbursement, which is effectively the market. The realistic Indian-supply lanes are three: active pharmaceutical ingredient and intermediate supply to Turkish manufacturers, specialty or niche finished products with no feasible local production, and finished generics routed through a local-partner fill-finish or licensed local-manufacture arrangement. M Care structures the offer around which of these fits your molecule rather than promising open finished-product access.
How does the localisation mandate affect an Indian supplier?
Since 2016 Türkiye has tied SGK reimbursement to a commitment to local production for molecules that can feasibly be made domestically. The policy was significant enough to trigger a WTO dispute, DS583, brought by the European Union. For an Indian exporter the practical consequence is that pure imported finished generics for high-volume molecules face a reimbursement and pricing wall. The workable responses are to supply the API or intermediate into a Turkish manufacturer's local production, to partner on local fill-finish, or to focus on specialty, oncology, and niche products where local production is not feasible. M Care advises on which route a given molecule qualifies for before any commitment.
What is the TİTCK registration timeline?
The statutory technical review is 210 days, or 180 for priority products, but in practice a clean dossier closes in roughly eight to twelve months once the review begins. The larger variable is the TİTCK on-site GMP inspection of the foreign manufacturing site, which is a prerequisite and can add twelve to eighteen months of lead time depending on the inspection queue. M Care plans Türkiye programmes against the GMP-inspection lead time first, because that, not the dossier review, is usually the gating step.
How do SGK reimbursement and reference pricing work?
SGK, the Social Security Institution, is effectively the single national payer. After marketing authorisation a product applies to SGK for reimbursement, assessed by the Medical and Economic Evaluation Committee. Pricing uses external reference pricing against a basket of European countries, historically France, Italy, Spain, Portugal, and Greece, converted to Turkish lira through an adjustment coefficient that has structurally suppressed prices, plus mandatory public-purchase discounts. The combination of the reference-price coefficient and lira volatility compresses margins, which is why the commercially sensible Indian lanes into Türkiye are API supply and specialty products rather than low-margin commodity finished generics.
What ports and airports do shipments use, and how is cold chain handled?
Air freight runs Mumbai to Istanbul Airport (IST), the Turkish Cargo hub, at roughly six hours forty-five minutes wheels-up with frequent departures; Turkish Cargo holds IATA CEIV Pharma certification at Istanbul, which matters for temperature-controlled biologicals and APIs. Sea freight routes to the Port of Mersin, the principal pharmaceutical seaport, at roughly fourteen to fifteen days from Mumbai or Mundra. Cold-chain product moves air via IST with active or passive shippers chosen against apron dwell. Secondary packaging and relabelling for the Turkish market must be performed at a TİTCK-authorised secondary-packaging facility inside Türkiye.
Is Turkish-language labelling required?
Yes. Labels and the patient information leaflet (kullanma talimatı) must be in Turkish, and the dossier carries the source-country SmPC with Turkish translation. Türkiye is also tightening packaging rules: risk pictograms and anti-tampering requirements from mid-2026, and a mandatory electronic leaflet with QR and 2D barcode from the start of 2027. Secondary packaging or relabelling to meet these requirements is done at a TİTCK-authorised facility in Türkiye, which the local MA holder arranges. M Care supplies primary product with English master-carton labelling and the documentation the Turkish partner needs to complete local packaging.
API supply, specialty finished goods, and local-partner routes
DMF-backed API supply
Türkiye's strong finished-dose industry still imports active ingredients and intermediates. We supply DMF-supported APIs to Turkish manufacturers on long-term contracts, the lane least affected by the localisation mandate.
Specialty and niche finished goods
Oncology, biologicals, and niche molecules not yet made locally, where finished import stays commercially viable because no domestic equivalent triggers the localisation rule.
Local-partner fill-finish
Where localisation closes finished import, we work with a Turkish manufacturing partner on contract fill-finish and technology transfer using Indian bulk, so the product satisfies local-production expectations.
Top categories we ship to Türkiye
Oncology
Cytotoxics, targeted therapies, and supportive-care lines for Turkish university and city hospitals where a specialty molecule is not yet produced locally.
Haematology & biologicals
Biologicals, biosimilars, and complex injectables where local fill-finish capacity is limited, prepared for TİTCK registration and SGK reimbursement review.
Antivirals
Specialty antivirals and hepatitis lines for hospital and SGK channels where the molecule sits outside Türkiye's local production.
CNS & neurology
Niche CNS and neurology molecules and specialist strengths not covered by the domestic generic base.
Anti-infectives
Second-line and specialist anti-infectives, including injectable antibiotics, where an import gap remains against local manufacture.
Diabetes & endocrine
Analogue insulins and endocrine specialties supplied cold-chain into Istanbul, with documentation for TİTCK and SGK.
Services Turkish buyers commonly bundle
CTD dossier preparation
CTD and eCTD assembly to TİTCK expectations, Modules 1 to 5, prepared for the GMP-inspection lead time Türkiye applies to overseas sites.
WHO-GMP compliance
GMP evidence packs that hold up to a TİTCK on-site inspection of the manufacturing site before registration proceeds.
Cold-chain validated supply
Validated 2 to 8°C lanes into Istanbul for biologicals and analogue insulins, active or passive packaging chosen against transit time.
Sourcing API, or bringing a specialty line into Türkiye? Send the molecule.
Send the molecule, whether you need API for local fill-finish or a specialty finished product, and the TİTCK status if you have one. A named person on the Mumbai desk replies inside one working day with the realistic lane, documentation scope, and a candid view on the localisation and timeline implications.